BMI View: Germany's large and expanding pharmaceutical market will continue to generate commercial
opportunities for drugmakers over the forecast period. While Germany's ongoing economic rebalancing
will continue to support robust domestic consumption indices, includi ..."
BMI View: Germany's pharmaceutical and healthcare markets will continue to expand over the next ten
years, translating into renewed commercial opportunities for drugmakers operating in the country. While
patented medicines will continue to account for the largest shar ..."
BMI View: Germany's macroeconomic environment will continue to be favourable for drugmakers and
healthcare operators through 2016. Buoyant private consumption and higher public expenditure, brought
about by migrant/refugee accommodation and social security payments, w ..."
BMI View: Germany continues to stand as the largest pharmaceutical market in the European region,
although modest growth rates due to cost containment measures will continue to weigh on drugmakers'
commercial opportunities. In regional terms, the German drug market is ..."
BMI View: As the German economy observes signs of a tentative long-term rebalancing in which private
consumption will play a more significant role in economic growth, recent improvements in high frequency
indicators have lead us to an upward revision of the pharmaceut ..."
BMI View: Germany, one of the largest single pharmaceutical markets in Europe and the wider OECD,
will continue to exhibit high and rising underlying demand for branded pharmaceuticals generated by an
ageing population with an increasing burden of chronic non-communic ..."
GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Germany". The report is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in ..."
BMI View: One of the largest markets in Europe, Germany will continue to experience rising demand for
pharmaceuticals, sustained by an ageing population with a strong bias towards patented medicines. In spite
of this, additional restrictions on reimbursement, tempered by govern ..."
BMI View: While Germany remains a very attractive market for drugmakers, recent regulatory
developments intended to reduce healthcare spending will intensify already fierce competition amongst
drugmakers, resulting in constrained revenues for less efficient innovators. While re ..."
BMI View: Germany's medicines pricing regime will continue to restrict drugmakers' revenue streams. The
AMNOG has proved to be tough, with the majority of medicine reimbursement prices lying under the
average of or below the lowest of the European reference country ba ..."